Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
2 ASX healthcare shares racing higher on positive updates
ASX All ords biotech stock explodes 120% on regulatory green light
Share Market News
Guess which ASX All Ords share just crashed 52% on a TGA update
It's not all bad news for ASX All Ords shares today. Here are some big winners
2 ASX healthcare shares smashing the All Ords today
The chair of this ASX All Ords company just sold $6.5 million of shares. What gives?
Rhythm Biosciences share price lifts 5% on TGA news
Here's why the Rhythm Biosciences (ASX:RHY) share price soared 8% today
Here's why the Rhythm (ASX:RHY) share price is up 11% today
Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets
Rhythm Biosciences (ASX: RHY) share price slumps amid 'pivotal' board changes
Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.
|08 Dec 2023||$0.16||$-0.02||-11.76%||84,250||$0.17||$0.17||$0.16|
|07 Dec 2023||$0.17||$-0.02||-10.53%||150,847||$0.19||$0.19||$0.17|
|06 Dec 2023||$0.19||$0.05||34.48%||114,732||$0.15||$0.20||$0.15|
|05 Dec 2023||$0.15||$-0.02||-12.31%||373,013||$0.16||$0.16||$0.13|
|04 Dec 2023||$0.16||$-0.01||-5.88%||33,051||$0.16||$0.17||$0.16|
|01 Dec 2023||$0.17||$0.00||0.00%||9,628||$0.16||$0.17||$0.16|
|30 Nov 2023||$0.17||$0.00||0.00%||53,584||$0.17||$0.17||$0.16|
|29 Nov 2023||$0.17||$0.00||0.00%||247,752||$0.18||$0.18||$0.17|
|28 Nov 2023||$0.18||$0.00||0.00%||54,154||$0.17||$0.18||$0.17|
|27 Nov 2023||$0.17||$0.00||0.00%||508,483||$0.18||$0.19||$0.17|
|24 Nov 2023||$0.18||$-0.01||-5.56%||26,423||$0.18||$0.18||$0.17|
|23 Nov 2023||$0.18||$0.01||5.71%||251,780||$0.18||$0.18||$0.17|
|22 Nov 2023||$0.18||$-0.02||-10.53%||276,211||$0.19||$0.19||$0.17|
|21 Nov 2023||$0.19||$0.01||5.41%||57,861||$0.19||$0.20||$0.19|
|20 Nov 2023||$0.19||$-0.02||-10.00%||328,886||$0.20||$0.20||$0.19|
|17 Nov 2023||$0.20||$0.02||11.11%||46,106||$0.19||$0.20||$0.19|
|16 Nov 2023||$0.18||$-0.02||-10.00%||667,370||$0.20||$0.21||$0.18|
|15 Nov 2023||$0.20||$-0.01||-4.76%||313,871||$0.23||$0.23||$0.20|
|14 Nov 2023||$0.21||$0.00||0.00%||154,138||$0.22||$0.23||$0.21|
|13 Nov 2023||$0.21||$0.02||10.26%||360,861||$0.20||$0.23||$0.20|
|10 Nov 2023||$0.20||$0.01||5.41%||470,739||$0.18||$0.21||$0.18|
|09 Nov 2023||$0.19||$-0.01||-5.26%||97,939||$0.19||$0.19||$0.18|
|10 Oct 2023||Sue(Susan) MacLeman||Issued||200,000||$61,000||
Issue of options.
|08 Aug 2023||Trevor Lockett||Buy||1,125,000||$225,000||
Exercise of options.
|08 Aug 2023||Trevor Lockett||Exercise||1,125,000||$225,000||
Exercise of options.
|30 Jun 2023||Otto Buttula||Expiry||500,000||$205,000||
|30 Jun 2023||Louis (Lou) Panaccio||Expiry||37,500||$15,375||
|30 Jun 2023||Trevor Lockett||Expiry||125,000||$51,250||
|12 May 2023||Otto Buttula||Buy||683,895||$248,245||
|18 Jan 2023||Glenn Gilbert||Issued||3,000,000||$2,925,000||
Employee Share Ownership Plan.
|18 Jan 2023||Rachel David||Issued||150,000||$146,250||
Issue of options.
|04 Jan 2023||Otto Buttula||Expiry||500,000||$530,000||
|04 Jan 2023||Louis (Lou) Panaccio||Expiry||37,500||$39,750||
|04 Jan 2023||Trevor Lockett||Expiry||125,000||$132,500||
|04 Jan 2023||Glenn Gilbert||Expiry||500,000||$530,000||
|Mr Otto Leslie Steven Buttula||Executive ChairmanExecutive Director||Oct 2019||
Mr Buttula has had experience in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Ltd. He is a Director of HITIQ Limited (appointed 28 January 2021) and OncoSil Medical Limited (appointed 20 July 2021).
|Mr Louis (Lou) James Panaccio||Non-Executive Director||Aug 2017||
Mr Panaccio has management experience in business and healthcare services. Mr Panaccio is also on the board of Unison Housing Ltd. Mr Panaccio has more than twenty years experience as a board member of both public and private, for profit and not for profit companies. Previously, Mr Panaccio was the CEO of Melbourne Pathology and Monash IVF, and executive Chairman of Health Networks Australia.
|Ms Sue(Susan) MacLeman||Non-Executive Director||Jan 2023||
Mr MacLeman has more than 30 years experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development at Schering Plough Corporation (now Merck), Amgen, Bristol Myers Squibb and Mesoblast. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector. Sue is currently the Chair of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect). Sue is a Non Executive Director of Planet Innovation Holdings Ltd, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Sue is also appointed to several academic and government advisory boards. Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management.
|Dr Trevor John Lockett||Technical director||Nov 2018||
Dr Lockett has postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Dr Lockett has led research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Dr Lockett oversaw the research efforts which led to the technology that is to become ColoSTAT.
|Dr Rachel David||Non-Executive Director||Dec 2021||
Dr David is an experienced senior health and financial services sector executive. Dr David is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA). Dr David's career has spanned over 25 years during which she has delivered value by promoting policy change to address the economic problems and market failures in healthcare, relating to evidence based practice and access to new technologies. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.
|Ms Andrea Steele||Company SecretaryGeneral Counsel||Feb 2022||
|Andrea Steele||Company SecretaryGeneral Counsel||
|Webinvest Pty Ltd||17,291,667||7.83%|
|Ferndale Securities Pty Ltd||10,300,000||4.66%|
|Loumea Investment Pty Ltd||8,052,520||3.65%|
|Northern Star Nominees Pty Ltd||7,380,000||3.34%|
|Newfound Investments Pty Ltd||6,819,729||3.09%|
|HSBC Custody Nominees (Australia) Limited||6,515,269||2.95%|
|Rojo Nero Capital Pty Ltd||4,323,751||1.96%|
|Giokir Pty Ltd||3,661,470||1.66%|
|Mr Hsien Michael Soo||3,305,403||1.50%|
|Commonwealth Scientific & Industrial Research Organisation||2,500,000||1.13%|
|Ms Natalie Louise Patterson||2,477,083||1.12%|
|E & W Nominee Pty Ltd||2,207,941||1.00%|
|Mr Daniel Eddington & Mrs Julie Eddington||2,123,532||0.96%|
|Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss||2,000,000||0.91%|
|Mrs Sarah Cameron||1,920,800||0.87%|
|Jawaf Enterprises Pty Ltd||1,875,000||0.85%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||1,662,733||0.75%|
|Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison||1,450,000||0.66%|
|Mr Richard Stanley De Ravin||1,448,228||0.66%|
|Mr Adrian Darby||1,357,124||0.61%|